Pamela Strode

Pamela Strode Regulatory Affairs Fulcrum Therapeutics Inc 3 years ago By Amber Wareing
  • Share on

  • Linkedin

Labelling at 9:00 am – 10:00 am Pamela Strode has a strong track record of successfully guiding the development and ultimate approval of multiple drug candidates. Her regulatory acumen and experience working on programs for underserved diseases have made her a wonderful asset to the Fulcrum team as they advance their clinical programs to improve the lives of people affected by genetic diseases, beginning with FSHD. Previously, Pamela Strode had moved to Fulcrum from Epizyme, Inc., where she served as senior vice president, regulatory affairs and quality assurance, and played a critical role in establishing the team’s regulatory affairs and quality assurance departments. At Epizyme, Strode directed multiple U.S. Fast Track and U.S./E.U. Orphan Drug Designations and also led the regulatory strategy and operations for several clinical trial applications and a New Drug Application (NDA). Strode brings more than 30 years of regulatory leadership for investigational and marketed products across multiple therapeutic areas, with increasing levels of responsibility at Bristol-Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Inc. and Cerulean Pharma. Pamela Strode received her Bachelor’s of Science in Microbiology from Rutgers, The State University of New Jersey-New Brunswick. She received her Masters from Tempe University.

More news